{
  "ticker": "VRTX",
  "company_name": "Vertex Pharmaceuticals Incorporated",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT06523595",
      "title": "Evaluation of the Pharmacokinetic Drug-drug Interactions Between VX-993 and Metformin in Healthy Adults",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Pain",
      "start_date": "2024-07-31",
      "completion_date": "2024-12-31",
      "enrollment": 0,
      "sponsor": "Vertex Pharmaceuticals Incorporated"
    },
    {
      "nct_id": "NCT04618185",
      "title": "Gut Imaging for Function & Transit in CF - GIFT-CF 3",
      "status": "COMPLETED",
      "phase": "",
      "condition": "Cystic Fibrosis",
      "start_date": "2020-10-21",
      "completion_date": "2023-06-28",
      "enrollment": 0,
      "sponsor": "Nottingham University Hospitals NHS Trust"
    },
    {
      "nct_id": "NCT00630058",
      "title": "A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Hepatitis C",
      "start_date": "2008-04",
      "completion_date": "2009-03",
      "enrollment": 0,
      "sponsor": "Tanabe Pharma Corporation"
    },
    {
      "nct_id": "NCT01863238",
      "title": "An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age or Younger With Cystic Fibrosis",
      "status": "COMPLETED",
      "phase": "",
      "condition": "Cystic Fibrosis",
      "start_date": "2013-05",
      "completion_date": "2016-05",
      "enrollment": 0,
      "sponsor": "Vertex Pharmaceuticals Incorporated"
    },
    {
      "nct_id": "NCT02953314",
      "title": "A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF)",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Cystic Fibrosis",
      "start_date": "2016-11",
      "completion_date": "2018-09",
      "enrollment": 0,
      "sponsor": "Vertex Pharmaceuticals Incorporated"
    },
    {
      "nct_id": "NCT04066751",
      "title": "The Multicenter Topic Trial",
      "status": "WITHDRAWN",
      "phase": "PHASE2",
      "condition": "Chronic Obstructive Pulmonary Disease",
      "start_date": "2021-12-01",
      "completion_date": "2024-10-31",
      "enrollment": 0,
      "sponsor": "University of Alabama at Birmingham"
    },
    {
      "nct_id": "NCT02971839",
      "title": "Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutations",
      "status": "TERMINATED",
      "phase": "PHASE2",
      "condition": "Cystic Fibrosis",
      "start_date": "2016-12",
      "completion_date": "2017-08",
      "enrollment": 0,
      "sponsor": "Vertex Pharmaceuticals Incorporated"
    },
    {
      "nct_id": "NCT03068312",
      "title": "A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C\u2192T or D1152H CFTR Mutation",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Cystic Fibrosis",
      "start_date": "2017-07-18",
      "completion_date": "2018-12-18",
      "enrollment": 0,
      "sponsor": "Vertex Pharmaceuticals Incorporated"
    },
    {
      "nct_id": "NCT04006873",
      "title": "Gut Imaging for Function & Transit in Cystic Fibrosis Study 2",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Cystic Fibrosis",
      "start_date": "2019-09-03",
      "completion_date": "2020-10-29",
      "enrollment": 0,
      "sponsor": "Nottingham University Hospitals NHS Trust"
    },
    {
      "nct_id": "NCT06345755",
      "title": "A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Autosomal Dominant Polycystic Kidney Disease (ADPKD)",
      "start_date": "2024-04-17",
      "completion_date": "2025-06-13",
      "enrollment": 0,
      "sponsor": "Vertex Pharmaceuticals Incorporated"
    }
  ],
  "summary": {
    "total_trials": 50,
    "by_phase": {
      "PHASE1": 12,
      "": 5,
      "PHASE3": 10,
      "PHASE2": 20,
      "PHASE1, PHASE2": 2,
      "PHASE2, PHASE3": 1
    },
    "by_status": {
      "COMPLETED": 42,
      "WITHDRAWN": 2,
      "TERMINATED": 2,
      "ACTIVE_NOT_RECRUITING": 1,
      "APPROVED_FOR_MARKETING": 1,
      "RECRUITING": 2
    },
    "active_trials": 3,
    "completed_trials": 42,
    "conditions": [
      "Acute Pain",
      "Alpha1-Antitrypsin Deficiency",
      "Autosomal Dominant Polycystic Kidney Disease (ADPKD)",
      "Chronic Hepatitis C",
      "Chronic Hepatitis C Virus",
      "Chronic Obstructive Pulmonary Disease",
      "Cystic Fibrosis",
      "Cystic Fibrosis, Homozygous for the F508del CFTR Mutation",
      "Diabetic Peripheral Neuropathic Pain",
      "Healthy Volunteers",
      "Hepatic Impairment, Healthy",
      "Hepatic Insufficiency",
      "Hepatitis C",
      "Hepatitis C, HIV Infections",
      "In Development for Cystic Fibrosis",
      "Pain",
      "Rheumatoid Arthritis",
      "Small Fiber Neuropathy",
      "Type 1 Diabetes"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-12T09:33:28.642625",
    "search_query": "Vertex Pharmaceuticals Incorporated",
    "url": "https://clinicaltrials.gov/search?term=Vertex+Pharmaceuticals+Incorporated"
  }
}